Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 21 peer-reviewed journal articles Updated
Urology

Life After Treatment and Long-Term Monitoring

At a Glance

After prostate cancer treatment, regular PSA testing helps detect recurrence, while follow-up care addresses urinary, sexual, bone, heart, and metabolic health. New severe back pain, leg weakness, saddle numbness, or bladder or bowel loss requires emergency evaluation.

Completing your initial treatment for prostate cancer is a major milestone, but it often marks the beginning of a new phase: survivorship. This period involves a shift from active intervention to long-term monitoring and managing the “new normal” of your physical and emotional health [1][2].

Watching the Numbers: PSA Monitoring

The most critical tool for monitoring your health after treatment is the PSA test. Because the prostate is the primary source of PSA, a rising level can be an early warning that cancer cells are active again [3].

  • The Schedule: Standard guidelines generally recommend a PSA test every 6 to 12 months for the first five years, and once a year thereafter [3][1]. Your doctor may suggest more frequent testing if you had high-risk disease [3].
  • Defining Recurrence: “Success” looks different depending on your treatment [4]:
    • After Surgery: Your PSA should ideally fall to “undetectable” levels (usually less than 0.1 or 0.2 ng/mL). A biochemical recurrence is typically defined as two consecutive tests where the PSA is 0.2 ng/mL or higher. However, this definition is not the safest time to act; in some high-risk patients, a single low detectable ultrasensitive value may prompt early salvage discussions before the formal threshold [5][4].
    • After Radiation: The prostate remains and benign tissue can produce PSA, so it drops slowly to its lowest point (the nadir). Recurrence is defined by the Phoenix criteria: a rise of 2.0 ng/mL or more above that lowest point. A slow decline, fluctuation, or a temporary “PSA bounce” does not automatically mean recurrence, though the clinician may investigate concerning trends before the formal threshold [5][4][6].

Reclaiming Your Quality of Life

Long-term side effects are common, and many can be managed with the right support.

  • Urinary Incontinence: After surgery, many men experience leakage. Pelvic Floor Muscle Training (PFME), often called Kegel exercises, is highly effective [7]. Working with a specialized physical therapist within the first six months can significantly speed up your recovery [8].
  • Erectile Dysfunction (ED): Recovery can take several years. While “penile rehabilitation” with medications like PDE-5 inhibitors (Viagra or Cialis) is common, its ability to speed up natural recovery is still being studied [9]. If pills don’t work, early referral for other options like injections, vacuum devices, or implants remains highly effective [10][11].
  • Hormone Therapy (ADT) Management: If you are on long-term ADT, your team should monitor you for metabolic syndrome (weight gain, high blood pressure, and blood sugar changes), cardiovascular risk, and bone loss [12][13]. A combination of resistance, balance, and weight-bearing exercise is recommended, alongside baseline fracture-risk assessment (DEXA) and individualized calcium/Vitamin D advice [14][12].

When to Seek Urgent Medical Help

While most follow-ups are routine, certain symptoms require immediate evaluation to prevent permanent damage.

Metastatic Spinal Cord Compression (MSCC)
This is a medical emergency that occurs if cancer spreads to the spine and presses on the spinal cord [15]. Go to the Emergency Room immediately if you experience:

  • New or worsening, severe back or neck pain that feels like a “band” around your body [16].
  • New weakness or heaviness in your legs, or difficulty walking [15].
  • Saddle Numbness: Loss of feeling in the areas that would touch a bike saddle (groin, buttocks, inner thighs) [17].
  • Sudden loss of bladder or bowel control [15].

A suspected spinal cord compression requires an urgent MRI of the entire spine, ideally within 24 hours, to determine if emergency surgery or radiation is needed to save your ability to walk [18][19].

Other Emergencies

  • Acute Urinary Retention: If you suddenly cannot urinate at all and feel severe pain in your lower abdomen, seek immediate care to have a catheter placed [20].
  • Pathological Fracture: Sudden, intense bone pain after a minor fall or even a normal movement may indicate a bone has broken because it was weakened by cancer [19][21].

What is NOT an Emergency (Usually)

It is natural to feel anxious about new symptoms, but the following are generally managed through scheduled appointments rather than the ER:

  • A rising PSA: While concerning, a rising PSA without physical symptoms is not an emergency. It takes time to confirm a trend and schedule a scan [1].
  • Mild Fatigue and Hot Flashes: These are standard side effects of hormone therapy when they are mild, stable, and already explained [2][1]. However, seek urgent medical help if fatigue is severe or rapidly worsening, or accompanied by fever, chest pain, shortness of breath, confusion, or inability to hydrate.
  • Mild Incontinence or ED: These are long-term quality-of-life issues. However, if symptoms rapidly worsen, report them sooner than a scheduled appointment [1].

Common questions in this guide

How often should I have a PSA test after prostate cancer treatment?
Many follow-up plans use a PSA test every 6 to 12 months during the first five years and once a year after that. People with higher-risk disease may need testing more often, so your schedule should be individualized by your clinician.
What PSA result suggests prostate cancer has returned after surgery?
After prostate removal, PSA is expected to fall to an undetectable or nearly undetectable level. A biochemical recurrence is commonly defined as a PSA of 0.2 ng/mL or higher on two consecutive tests, but a rising low-level result may lead some clinicians to discuss additional treatment sooner.
Does a rising PSA after radiation always mean recurrence?
No. Because the prostate remains after radiation, PSA can decline slowly, fluctuate, or briefly rise in a temporary PSA bounce. Recurrence is commonly defined as a rise of at least 2.0 ng/mL above the lowest PSA level reached, but concerning trends may be evaluated earlier.
Which symptoms after prostate cancer treatment require emergency care?
Seek emergency care for new or worsening severe back or neck pain, leg weakness, trouble walking, numbness in the groin or inner thighs, sudden loss of bladder or bowel control, or an inability to urinate with severe lower abdominal pain. These symptoms can signal pressure on the spinal cord or acute urinary retention, which need urgent treatment.
How should long-term hormone therapy be monitored?
Long-term androgen deprivation therapy should be monitored for weight gain, blood pressure and blood sugar changes, cardiovascular risk, and bone loss. Follow-up may include fracture-risk assessment such as a DEXA scan, individualized calcium and vitamin D advice, and resistance, balance, and weight-bearing exercise.
What can help with incontinence or erectile dysfunction after treatment?
Pelvic floor muscle training and guidance from a specialized physical therapist can help urinary leakage after surgery. Erectile dysfunction may be treated with medicines such as Viagra or Cialis, and if those do not help, injections, vacuum devices, or implants are options to discuss with a clinician.
Is a rising PSA without symptoms an emergency?
Usually not. A rising PSA needs prompt contact with your treatment team and repeat testing or imaging as appropriate, but it is generally managed through an outpatient appointment unless you also have emergency symptoms such as severe back pain, weakness, or loss of bladder or bowel control.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific treatment, at what exact PSA level or pattern of rise would we begin discussing salvage treatments?
  2. 2.What is our specific plan for monitoring my bone health (e.g., DEXA scans) and cardiovascular risk while I am on hormone therapy?
  3. 3.Can you refer me to a physical therapist who specializes in pelvic floor rehabilitation to help with urinary recovery?
  4. 4.If my PSA starts to rise, what is your threshold for ordering a PSMA PET/CT scan to locate the recurrence?
  5. 5.What are the escalating options for erectile dysfunction if standard oral medications aren't working for me?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (21)
  1. 1

    Primary Care of the Prostate Cancer Survivor.

    Noonan EM, Farrell TW

    American family physician 2016; (93(9)):764-70.

    PMID: 27175954
  2. 2

    Patient-reported 'ever had' and 'current' long-term physical symptoms after prostate cancer treatments.

    Gavin AT, Drummond FJ, Donnelly C, et al.

    BJU international 2015; (116(3)):397-406 doi:10.1111/bju.13036.

    PMID: 25597493
  3. 3

    Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement.

    Resnick MJ, Lacchetti C, Bergman J, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015; (33(9)):1078-85 doi:10.1200/JCO.2014.60.2557.

    PMID: 25667275
  4. 4

    EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.

    Cornford P, Bellmunt J, Bolla M, et al.

    European urology 2017; (71(4)):630-642 doi:10.1016/j.eururo.2016.08.002.

    PMID: 27591931
  5. 5

    68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy - diagnostic performance and impact on therapeutic decision-making.

    Grubmüller B, Baltzer P, D'Andrea D, et al.

    European journal of nuclear medicine and molecular imaging 2018; (45(2)):235-242 doi:10.1007/s00259-017-3858-2.

    PMID: 29075832
  6. 6

    Prostate-specific antigen (PSA) bounce following salvage radiotherapy to the prostate bed in a patient with prostate cancer post-prostatectomy.

    Rowe M, Adamson E, McGrane J

    International cancer conference journal 2020; (9(4)):217-220 doi:10.1007/s13691-020-00428-0.

    PMID: 32904120
  7. 7

    Supervised pelvic floor muscle exercise is more effective than unsupervised pelvic floor muscle exercise at improving urinary incontinence in prostate cancer patients following radical prostatectomy - a systematic review and meta-analysis.

    Baumann FT, Reimer N, Gockeln T, et al.

    Disability and rehabilitation 2022; (44(19)):5374-5385 doi:10.1080/09638288.2021.1937717.

    PMID: 34550846
  8. 8

    British Association of Urological Surgeons (BAUS) consensus document on post-prostatectomy incontinence-stress urinary incontinence.

    Bhatt NR, Biers S, Sahai A, et al.

    BJU international 2025; (135(6)):887-901 doi:10.1111/bju.16726.

    PMID: 40171684
  9. 9

    Sexual Rehabilitation After Treatment For Prostate Cancer-Part 2: Recommendations From the Fourth International Consultation for Sexual Medicine (ICSM 2015).

    Salonia A, Adaikan G, Buvat J, et al.

    The journal of sexual medicine 2017; (14(3)):297-315 doi:10.1016/j.jsxm.2016.11.324.

    PMID: 28262100
  10. 10

    Erectile dysfunction after radical prostatectomy: prevalence, medical treatments, and psychosocial interventions.

    Emanu JC, Avildsen IK, Nelson CJ

    Current opinion in supportive and palliative care 2016; (10(1)):102-7 doi:10.1097/SPC.0000000000000195.

    PMID: 26808052
  11. 11

    Simultaneous implant of inflatable penile prosthesis and artificial urinary sphincter: a single high-volume center experience.

    Van Huele A, Van Renterghem K

    International journal of impotence research 2025; (37(1)):78-81 doi:10.1038/s41443-023-00718-0.

    PMID: 37188772
  12. 12

    Adverse effects of androgen deprivation therapy in patients with prostate cancer: focus on metabolic complications.

    Tzortzis V, Samarinas M, Zachos I, et al.

    Hormones (Athens, Greece) 2017; (16(2)):115-123 doi:10.14310/horm.2002.1727.

    PMID: 28742500
  13. 13

    Effect of Androgen Deprivation Therapy on Metabolic Complications and Cardiovascular Risk.

    Melloni C, Nelson A

    Journal of cardiovascular translational research 2020; (13(3)):451-462 doi:10.1007/s12265-019-09942-w.

    PMID: 31833002
  14. 14

    Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials.

    Teleni L, Chan RJ, Chan A, et al.

    Endocrine-related cancer 2016; (23(2)):101-12 doi:10.1530/ERC-15-0456.

    PMID: 26584972
  15. 15

    Evidence-based management of metastatic spinal cord compression (MSCC): expert recommendations for standardizing care in Spain.

    Conde-Moreno AJ, Pérez-Lara A, Ferrer-Abiach C, et al.

    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2026; doi:10.1007/s12094-026-04345-1.

    PMID: 42228280
  16. 16

    [Malignant Spinal Cord Compression].

    Aoyama Y, Kondoh C, Anno M, et al.

    Gan to kagaku ryoho. Cancer & chemotherapy 2020; (47(6)):875-880.

    PMID: 32541159
  17. 17

    Assessment and Management of Patients With Metastatic Spinal Cord Compression: A Multidisciplinary Review.

    Lawton AJ, Lee KA, Cheville AL, et al.

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2019; (37(1)):61-71 doi:10.1200/JCO.2018.78.1211.

    PMID: 30395488
  18. 18

    Narrative review-diagnosing and managing malignant epidural spinal cord compression: an evidence-based approach.

    Akanda ZZ, McKay MJ

    Annals of translational medicine 2023; (11(11)):386 doi:10.21037/atm-22-3076.

    PMID: 37970608
  19. 19

    Imaging of spinal metastases: modality performance, complications, and differential diagnosis.

    Beaufort Q, Lefevre V, Carsuzaa T

    Neuro-Chirurgie 2026; (72(3)):101804 doi:10.1016/j.neuchi.2026.101804.

    PMID: 41903774
  20. 20

    Urinary Retention in Adults: Evaluation and Initial Management.

    Serlin DC, Heidelbaugh JJ, Stoffel JT

    American family physician 2018; (98(8)):496-503.

    PMID: 30277739
  21. 21

    Spinal Instability as a Prognostic Factor in Patients With Spinal Metastasis of Castration-resistant Prostate Cancer.

    Miyaji Y, Nakanishi K, Yamamoto A, et al.

    Cancer diagnosis & prognosis 2023; (3(4)):449-456 doi:10.21873/cdp.10238.

    PMID: 37405221

This page provides general information about life after prostate cancer treatment, PSA surveillance, side effects, and warning signs; it is for informational purposes only and does not constitute medical advice. Follow your own care team’s plan, and seek emergency help for sudden weakness, loss of bladder or bowel control, or inability to urinate.

Get notified when new evidence is published on prostate adenocarcinoma.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.